Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies

• Published in: European journal of pharmaceutical sciences Vol. 45; no. 4; pp. 399 - 407
• Main Authors: Altintas, Isil, Kok, Robbert Jan, Schiffelers, Raymond M.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Kindlington Elsevier B.V 12.03.2012; Elsevier
• Subjects: Animals; Antibodies - pharmacology; Antibodies - therapeutic use; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibody; Biological and medical sciences; Drug delivery systems; Epidermal growth factor receptor; General pharmacology; Humans; Immunoglobulin Heavy Chains - pharmacology; Immunoglobulin Heavy Chains - therapeutic use; Medical sciences; Nanobody; Nanoparticles - therapeutic use; Neoplasms - drug therapy; Neoplasms - metabolism; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Receptor, Epidermal Growth Factor - metabolism; HSA NP; P(MDS-co-CES); NP; Drug delivery systems; CDC; PLA; IHC; EPR; Au NP; EGFR; Epidermal growth factor receptor; CDR; DDS; PTX; BSH; ADCC; HCAb; ICP-AES; Nanobody; Antibody; DOX; Tar. Lig; pIgG; mAb; mPEG-b; VH; PLGA; TKI; VL; PG; p(HPMAm-Lacn); Heavy peptide chain; Target; Pharmaceutical technology; Targeting; Drug carrier; Monoclonal antibody; Malignant tumor; Cancer
• ISSN: 0928-0987; 1879-0720; 1879-0720
• DOI: 10.1016/j.ejps.2011.10.015

The discovery of naturally occurring heavy chain only antibodies and their further development into small recombinant ‘nanobodies’ offers attractive applications in drug targeting. Here, we describe the properties of nanobodies that have been developed to target the epidermal growth factor receptor (EGFR) and contrast these to the characteristics of heavy chain only antibodies and conventional antibodies. EGFR is overexpressed in many tumors and is an attractive target for tumor-directed drug targeting.